A Comprehensive Report on Modified Vaccinia Ankara (MVA): From Attenuated Smallpox Vaccine to a Modern Vector Platform

1.0 Executive Summary

Modified Vaccinia Ankara (MVA) represents a landmark achievement in vaccinology, evolving from a highly attenuated, third-generation smallpox vaccine into a versatile and robust platform for developing vaccines against a range of infectious diseases and for novel cancer immunotherapies. Its defining characteristic is an exceptional safety profile, rooted in its inability to replicate in mammalian cells, which is a direct consequence of its unique development history involving over 500 serial passages in avian cells. This process induced significant genomic deletions, stripping the virus of key virulence and host-range factors while preserving its immunogenicity.

As a vaccine against orthopoxviruses, MVA-BN (marketed as JYNNEOS, IMVANEX, and IMVAMUNE) has demonstrated safety and immunogenicity in an extensive clinical trial program involving thousands of participants. Its critical role was validated during the 2022-2023 global mpox outbreak, where it became the primary prophylactic tool, particularly for high-risk and immunocompromised populations for whom older, replication-competent smallpox vaccines are contraindicated. Real-world data from this period confirmed its favorable safety profile and demonstrated vaccine effectiveness ranging from 66% to 89% for a complete two-dose course.

Beyond its primary indication, MVA serves as a potent viral vector. Its large genome can accommodate foreign antigens, and its abortive infection cycle in human cells allows for robust antigen expression, stimulating both humoral and cellular immunity without the risk of productive infection or insertional mutagenesis. This has led to its investigation in numerous clinical trials for complex pathogens such as HIV and Ebola, with one recombinant MVA-based Ebola vaccine (Mvabea) receiving regulatory approval in Europe. Furthermore, its ability to deliver tumor-associated antigens has positioned MVA as a promising vector for cancer immunotherapy. This report provides a comprehensive analysis of MVA's molecular biology, clinical development, comparative safety, regulatory status, and its expanding role in modern medicine.

2.0 Introduction: The Genesis of a Third-Generation Poxvirus Vaccine

The development of Modified Vaccinia Ankara is a story of deliberate scientific innovation, born from the necessity to overcome the significant safety limitations of its predecessors. While the global eradication of smallpox stands as one of public health's greatest triumphs, the very tool that made it possible—the conventional vaccinia virus vaccine—carried inherent risks that curtailed its use in a post-eradication world and in special populations.

2.1 The Legacy and Limitations of First- and Second-Generation Smallpox Vaccines

The first-generation smallpox vaccine, a live, replication-competent vaccinia virus (e.g., Dryvax), was highly effective but also highly reactogenic.[1] Its use was associated with a range of severe and sometimes fatal adverse events, including progressive vaccinia (an uncontrolled, spreading infection in immunocompromised individuals), eczema vaccinatum (a severe rash in those with skin conditions like atopic dermatitis), and post-vaccinial encephalitis.[3] While the mortality rate was low relative to the scale of vaccination—estimated at one to two deaths per million vaccinated—these risks became unacceptable once the threat of endemic smallpox was eliminated.[1]

The second-generation vaccine, ACAM2000, was developed to provide a more standardized, cell-culture-derived alternative to the calf-lymph-derived Dryvax.[6] Approved by the U.S. Food and Drug Administration (FDA) in 2007, ACAM2000 is also a live, replication-competent vaccinia virus.[3] Although it offered manufacturing consistency, it retained the fundamental safety concerns of a replicating virus. A significant risk associated with ACAM2000 is myopericarditis (inflammation of the heart muscle or surrounding tissue), with an observed rate in clinical studies of approximately 1 in 175 primary vaccinees.[3] Due to these risks, ACAM2000 is contraindicated in numerous populations, including individuals with weakened immune systems (e.g., HIV infection), certain skin conditions, and pregnant women.[4] This safety profile rendered it unsuitable for universal use in a biodefense scenario, creating a critical public health gap for protecting vulnerable populations.

2.2 The Development of Modified Vaccinia Ankara: A Paradigm of Viral Attenuation

The quest for a safer smallpox vaccine led researchers in Germany to pursue a strategy of extensive viral attenuation. Between 1953 and 1968, a team led by Professor Anton Mayr at the University of Munich took a strain of vaccinia virus known as Chorioallantois Vaccinia Ankara (CVA), which was in use in Turkey, and subjected it to a methodical process of adaptation.[2] This process involved more than 500 serial passages—repeated cycles of infection and harvesting—in primary chicken embryo fibroblast (CEF) cells.[2]

This classical virological technique imposed strong selective pressure on the virus to optimize its replication in avian cells. A direct consequence of this adaptation was the progressive loss of its ability to replicate efficiently in mammalian cells.[5] The resulting strain was named Modified Vaccinia Ankara (MVA). This "naturalistic" attenuation, achieved through selection rather than targeted genetic deletion, represents a bridge between classical and modern vaccine development. This approach likely contributed to its initial regulatory and clinical acceptance, as it was perceived as an evolution of existing methods rather than a radical departure.

The profound attenuation of MVA was confirmed in early studies. Unlike its parental CVA strain, MVA failed to produce the typical skin lesions upon inoculation.[11] Its safety was rigorously tested, and in the late 1970s, it was used to vaccinate over 120,000 people in Germany, including high-risk individuals such as children and the immunocompromised, with no reports of severe adverse events.[2] This early clinical experience provided the first large-scale evidence that MVA had achieved the desired balance: a high degree of safety without completely sacrificing immunogenicity. This foundational work laid the groundwork for MVA's eventual development by the company Bavarian Nordic into the modern MVA-BN vaccine, a cornerstone of contemporary orthopoxvirus preparedness.[2]

3.0 Molecular Biology and Immunological Profile

The exceptional safety and efficacy of MVA are direct results of the profound molecular changes it underwent during its attenuation. These genetic alterations fundamentally rewired its interaction with mammalian host cells, creating a virus that can effectively stimulate the immune system without causing disease.

3.1 Genomic Architecture: The Consequences of Serial Passage and Gene Loss

The extensive passaging of the ancestral CVA virus in avian cells resulted in a significant reduction of its genome. Genomic analyses have revealed that MVA lost approximately 10% to 15% of its genetic material, shrinking the genome from about 208 kilobases (kb) in CVA to around 177 kb in MVA.[2] This reduction was not random; it included six major genomic deletions, ranging from 2.6 kb to 10.2 kb, along with numerous smaller deletions, insertions, and point mutations.[10]

These mutations led to the fragmentation, truncation, or complete deletion of many open reading frames (ORFs).[10] Critically, many of the lost genes were non-essential for viral replication in cell culture but played key roles in pathogenesis and immune evasion in a mammalian host. MVA no longer encodes many of the virulence factors that conventional vaccinia viruses use to conquer their host environment, such as viral mimics of host receptors for key immune signaling molecules like $\gamma$-interferon, $\alpha/\beta$ interferons, and CC chemokines.[10] The loss of these immunomodulatory proteins means the virus is less capable of suppressing the host's innate and adaptive immune responses, contributing to its high immunogenicity relative to its safety.

3.2 The Mechanism of Host Range Restriction: An Abortive Replication Cycle in Mammalian Cells

The most important functional consequence of MVA's genomic alterations is its inability to complete its replication cycle in most mammalian cells, a phenomenon known as host range restriction.[2] The MVA life cycle in a human cell is abortive. The virus can successfully enter the host cell, and its molecular machinery proceeds through the initial stages of infection: the viral genome is uncoated, and all classes of viral genes—early, intermediate, and late—are expressed.[2] This allows for the production of viral proteins, including any foreign antigens engineered into the MVA genome when it is used as a vector.

However, the process is arrested at the final, crucial step of virion assembly.[2] While immature virus particles are formed within the cell's cytoplasm, they fail to mature into infectious progeny and are not released from the cell.[2] This block prevents the virus from spreading to neighboring cells and establishing a productive infection. Research has pinpointed the loss of specific host-range genes as the molecular basis for this late-stage restriction. In particular, the absence of functional C12L and C16L/B22R genes has been identified as necessary to restore MVA's ability to replicate productively in human cells, as these genes are involved in the processing of late structural proteins required for virion maturation.[13]

3.3 Stimulation of the Host Immune System: Eliciting Durable Humoral and Cellular Responses

MVA's abortive replication cycle represents an immunological sweet spot, providing the ideal balance between safety and immunogenicity. A fully replicating virus like ACAM2000 generates a strong immune response but poses significant safety risks.[3] Conversely, non-infectious subunit or killed vaccines are very safe but are often less immunogenic and require potent adjuvants. MVA occupies a unique and highly advantageous middle ground.

By entering host cells and expressing a full complement of viral proteins, MVA effectively mimics the early stages of a natural infection.[11] This process is highly effective at presenting viral antigens to the immune system, leading to the activation of both major arms of the adaptive immune response. The body mounts a robust humoral response, generating high titers of neutralizing antibodies that can block future infections, as well as a strong and polyfunctional cellular response, characterized by both CD4+ helper T cells and CD8+ cytotoxic T cells that can identify and eliminate infected cells.[5]

Furthermore, MVA possesses intrinsic adjuvant properties. The presence of viral DNA in the cytoplasm of infected cells is detected by the host's innate immune sensors, such as the cGAS-STING pathway, which triggers an initial inflammatory response.[5] This innate activation provides the "danger signals" necessary to prime and amplify the subsequent adaptive T-cell and B-cell responses. By failing to complete its replication cycle, MVA provides these potent immunological stimuli without causing the actual danger of a spreading infection. This elegant balance is the core of its value, making it an exceptionally safe yet highly effective vaccine and vaccine vector.

4.0 Clinical Profile: MVA-BN as a Prophylactic Vaccine for Smallpox and Mpox

The MVA strain further developed and manufactured by the Danish company Bavarian Nordic, known as MVA-BN, is the basis for the licensed vaccines JYNNEOS (in the U.S.), IMVANEX (in Europe), and IMVAMUNE (in Canada).[2] This product has undergone extensive clinical evaluation, establishing its role as the premier vaccine for preventing disease caused by orthopoxviruses, including smallpox and mpox.

4.1 Evidence from Pivotal Clinical Trials: A Review of Safety and Immunogenicity Data

The regulatory approval of MVA-BN was supported by a comprehensive clinical development program comprising over 22 studies and involving more than 7,800 individuals, including both smallpox vaccine-naïve and vaccine-experienced participants.[3] These trials consistently demonstrated a favorable safety and tolerability profile. The most commonly reported adverse reactions were mild-to-moderate and transient, resolving within a week. These included injection site reactions such as pain (reported by up to 85% of participants), redness (up to 61%), swelling (up to 52%), and itching (up to 43%), as well as systemic symptoms like muscle pain (up to 43%), headache (up to 35%), and fatigue (up to 30%).[21] Crucially, the serious adverse events of special interest associated with older replicating vaccines—such as myocarditis, pericarditis, progressive vaccinia, and encephalitis—were not observed in the MVA-BN clinical trials.[3]

Because it would be unethical to conduct efficacy trials with live smallpox or mpox virus in humans, the effectiveness of MVA-BN was established based on immunogenicity data, primarily the levels of vaccinia-neutralizing antibodies generated after vaccination.[21] Pivotal studies demonstrated that the peak antibody response induced by a two-dose course of MVA-BN was non-inferior to that produced by a single dose of the replication-competent ACAM2000 vaccine, meeting the regulatory endpoint for approval.[22] Further evidence for its protective efficacy came from animal challenge studies, where 80-100% of MVA-BN-vaccinated non-human primates survived a lethal mpox virus challenge, compared to 0-40% survival in the control groups.[22]

Table 4.1: Summary of Key Clinical Trials for MVA-BN in Smallpox/Mpox Prevention
ClinicalTrials.gov Identifier
Study 1 (as described in package insert)
Study 2 (as described in package insert)
NCT05740982
Multiple Studies (pooled data)

4.2 Real-World Effectiveness and Post-Marketing Surveillance from the Global Mpox Outbreak

The global mpox outbreak that began in 2022 provided an unprecedented opportunity to evaluate the real-world performance of MVA-BN. With nearly one million doses administered in the United States alone during the initial phase of the outbreak, extensive post-marketing data were collected.[29] Observational case-control studies conducted during this period provided the first estimates of vaccine effectiveness (VE) in humans. These studies suggested that a full two-dose primary series of JYNNEOS was 66% to 89% effective at preventing mpox disease.[22] One analysis found that the incidence of mpox was 9.6 times higher among unvaccinated men compared to those who had received two vaccine doses.[32]

Post-marketing safety surveillance from the CDC's Vaccine Adverse Event Reporting System (VAERS) and Vaccine Safety Datalink (VSD) corroborated the favorable safety profile seen in clinical trials.[29] The vast majority of reported adverse events were non-serious and consistent with the known reactogenicity profile, such as injection site reactions. Serious adverse events were rare, and importantly, no new or unexpected safety signals emerged despite widespread use. The rate of myocarditis and pericarditis reports was consistent with expected background rates in the population, providing further reassurance of the vaccine's cardiac safety compared to ACAM2000.[22]

4.3 Dosing Regimens, Administration Routes, and Use in Special Populations

The standard, approved dosing regimen for MVA-BN is a primary series of two 0.5 mL doses administered subcutaneously, 28 days apart.[2] However, faced with limited vaccine supply during the 2022 mpox outbreak, public health authorities implemented a dose-sparing strategy. On August 9, 2022, the U.S. FDA issued an Emergency Use Authorization (EUA) allowing for an alternative regimen for adults: two 0.1 mL doses administered intradermally.[2] This strategy allowed up to five doses to be extracted from a single standard vial. The decision was based on a 2015 clinical study which demonstrated that the lower intradermal dose produced a similar immune response to the standard subcutaneous dose.[33] While immunologically equivalent, the intradermal route was associated with a higher incidence of local reactions like redness, firmness, and itching, but less injection site pain.[33]

A key advantage of MVA-BN is its suitability for special populations. Clinical trials have confirmed its safety in individuals with atopic dermatitis and in people with HIV infection with CD4 counts as low as 100 cells/µL.[3] While the immune response may be diminished in severely immunocompromised individuals, the vaccine's safety makes it the only viable option for these groups, and it is recommended for them if they are at high risk of exposure.[21] Following the 2022 outbreak, the indication for MVA-BN has been expanded to include adolescents. Based on data from trial NCT05740982 showing non-inferior immunogenicity and a similar safety profile to adults, the European Medicines Agency (EMA) approved IMVANEX for individuals aged 12 to 17 in 2024.[20] The FDA's EUA also allows for its use in individuals younger than 18 years.[3] Clinical trials to assess its use in even younger children are underway.[20]

5.0 The MVA Vector Platform: Applications Beyond Orthopoxviruses

Beyond its role as a direct vaccine against smallpox and mpox, MVA's unique biological properties make it an ideal platform technology for developing recombinant vaccines against other pathogens and for cancer immunotherapy. Its ability to safely enter human cells, express foreign genes at high levels, and stimulate a broad immune response has made it a leading candidate vector in modern vaccinology.

5.1 Engineering Recombinant MVA for Infectious Disease Prophylaxis

MVA possesses several key advantages as a vaccine vector [15]:

• Safety: Its non-replicating nature in humans provides an excellent safety profile, even in immunocompromised individuals.[15]
• Large Insertion Capacity: The MVA genome is large and can accommodate the insertion of multiple foreign genes, allowing for the development of multivalent vaccines that target several antigens or even multiple pathogens simultaneously.[5]
• Potent Immunogenicity: It induces both strong antibody and T-cell responses to the inserted foreign antigens without the need for additional adjuvants.[5]
• Cytoplasmic Replication: The entire viral life cycle occurs in the cytoplasm, eliminating the risk of insertional mutagenesis, where viral DNA could integrate into the host cell's genome.[19]
• Low Pre-existing Immunity: Because routine smallpox vaccination ceased decades ago, most of the global population has no pre-existing immunity to the vaccinia vector, which allows for a more robust response to the vectored vaccine.[15]

These attributes have led to MVA's use in numerous investigational vaccines:

• HIV: MVA has been extensively studied as a vector for an HIV vaccine, often as part of a heterologous prime-boost strategy where a DNA vaccine is used for the initial prime and an MVA-based vaccine for the boost. Several Phase 1 and 2 clinical trials have evaluated candidates like MVA-B and MVA-CMDR, which express various HIV antigens, demonstrating their safety and ability to elicit anti-HIV immune responses.[2]
• Ebola: The MVA platform has achieved regulatory success in the fight against Ebola. The vaccine Mvabea (MVA-BN-Filo) is a recombinant MVA engineered to express proteins from the Zaire ebolavirus and other related filoviruses. It is approved by the EMA for use in individuals aged one year and older as the second dose in a two-part prime-boost regimen with Zabdeno, an adenovirus-vectored vaccine.[20]
• Other Pathogens: The versatility of the MVA vector has been demonstrated in preclinical and early clinical studies for a wide range of other challenging diseases, including malaria, tuberculosis, influenza, and measles.[2]

A critical consideration for the future of MVA-vectored vaccines arises from the intersection of its dual uses. The widespread use of MVA-BN as a vaccine during the 2022-2023 mpox outbreak has created a growing cohort of individuals with pre-existing immunity to the MVA vector itself.[29] This vector immunity could potentially blunt the immune response to a different MVA-vectored vaccine (e.g., for HIV) administered to these individuals in the future. This dynamic creates a novel public health challenge where a person's mpox vaccination history may become a relevant factor in their eligibility or expected response to other MVA-based vaccines, requiring careful consideration in future clinical trial design and vaccination strategies.

5.2 MVA in Oncology: A Vector for Cancer Immunotherapy

The same principles that make MVA an effective vector for infectious diseases are being applied to cancer immunotherapy. The goal is to use MVA to deliver tumor-associated antigens (TAAs)—proteins that are overexpressed on cancer cells—to the immune system in a way that breaks immune tolerance and stimulates a potent, targeted attack against the tumor.[19] The MVA vector essentially acts as a delivery vehicle to "teach" the immune system, particularly CD8+ T cells, to recognize and kill cancer cells.

Several MVA-based cancer vaccines are in clinical development. One prominent example is a vaccine engineered to express the TAA brachyury, a protein highly expressed in various solid tumors but not in most healthy adult tissues.[46] This MVA-Brachyury vaccine, often co-expressing other immune-stimulating molecules (TRICOM), has been tested in Phase 1 trials for patients with advanced solid tumors, including prostate, breast, and lung cancer.[46] Another approach has been to target the MUC1 antigen in renal cell carcinoma.[41] Studies are also exploring optimal administration routes, with evidence suggesting that intravenous (IV) injection may lead to faster and more widespread antigen expression in immune organs like the spleen, potentially generating a more rapid and effective anti-tumor T-cell response compared to standard subcutaneous injection.[41] Furthermore, there is strong preclinical rationale for combining MVA-based cancer vaccines with other immunotherapies, such as immune checkpoint inhibitors, to create a synergistic anti-tumor effect.[5]

5.3 Analysis of Investigational MVA-Based Candidates in Clinical Development

The breadth of the MVA platform is evident in the range of diseases it is being tested against in clinical trials. Beyond the examples above, MVA has been evaluated in:

• Hepatocellular Carcinoma: A Phase 2 trial (NCT00554372) investigated a recombinant vaccinia virus for the treatment of unresectable primary liver cancer.[48]
• Melanoma: A Phase 1/2 trial (NCT00116597) explored active specific intranodal immunotherapy using a recombinant MVA in patients with advanced metastatic melanoma.[49]

These trials, along with those for HIV and various solid tumors, underscore the scientific community's confidence in MVA's potential as a foundational technology for addressing some of the most difficult challenges in medicine.

6.0 Comparative Safety and Risk-Benefit Assessment

A central element of MVA-BN's value proposition is its vastly superior safety profile when compared to previous generations of smallpox vaccines. This favorable risk-benefit balance has established it as the preferred vaccine for orthopoxvirus protection in the modern era.

6.1 A Head-to-Head Comparison: MVA-BN (JYNNEOS) versus ACAM2000

The decision by public health authorities like the U.S. CDC to recommend JYNNEOS as the primary vaccine for mpox is rooted in a direct comparison of its characteristics against the second-generation ACAM2000 vaccine.[3] The fundamental difference lies in their ability to replicate in the human host. MVA-BN is replication-deficient, while ACAM2000 is replication-competent, a distinction that drives nearly all other differences in their safety and administration profiles.

Table 6.1: Comparative Profile of MVA-BN (JYNNEOS) and ACAM2000
Feature
Virus Type
Replication in Host
Administration
"Take" Lesion
Use in Immunocompromised
Use in Atopic Dermatitis
Risk of Myocarditis/Pericarditis
Risk of Transmission to Contacts

6.2 Comprehensive Adverse Event Profile and Management

The adverse event profile for MVA-BN is well-characterized from its extensive clinical trial program and large-scale post-marketing use.

• Common Adverse Events: The most frequent side effects are mild to moderate and self-limiting. They include injection site reactions (pain, redness, swelling, induration, itching) and systemic symptoms (fatigue, headache, myalgia, nausea, chills).[21] These reactions are a normal sign of the immune system responding to the vaccine.
• Serious Adverse Events: Serious adverse events causally related to MVA-BN are very rare. Across all clinical trials, only a handful of non-fatal serious events were reported for which a causal relationship could not be excluded, including cases of Crohn's disease, sarcoidosis, and throat tightness.[22]
• Cardiac Safety: Unlike ACAM2000, MVA-BN has not been associated with a clear increased risk of myocarditis or pericarditis. While isolated cases have been reported in post-marketing surveillance, the rates are low and consistent with what would be expected in the general population.[3] Clinical trial data did not suggest an increased cardiac risk compared to placebo.[3]

6.3 Clinically Significant Drug Interactions and Contraindications

The primary contraindication for MVA-BN is a history of a severe allergic reaction (e.g., anaphylaxis) to a previous dose of the vaccine or to any of its components.[36] The vaccine contains trace residual amounts of manufacturing components, including gentamicin, ciprofloxacin, and egg protein, so a history of severe allergy to these substances is a precaution.[9]

The most significant category of drug interactions involves immunosuppressive medications. Because MVA-BN relies on a competent immune system to generate a protective response, its therapeutic efficacy can be diminished when used in combination with drugs that suppress immune function.[18] This includes a wide range of therapies, such as:

• Biologics: Anifrolumab, baricitinib, basiliximab, bimekizumab, certolizumab pegol.
• Corticosteroids: Betamethasone, ciclesonide.
• Chemotherapeutic Agents: Bexarotene, blinatumomab, bortezomib, bosutinib, capecitabine, carboplatin, carfilzomib, carmustine, cisplatin.
• Other Immunosuppressants: Antilymphocyte immunoglobulin, antithymocyte immunoglobulin.[18]

In clinical practice, the decision to vaccinate an individual on such therapies requires a careful risk-benefit assessment, weighing the potential for a suboptimal vaccine response against the risk of contracting the disease.

7.0 The Global Regulatory and Public Health Landscape

MVA-BN has transitioned from a niche biodefense product to a globally recognized public health tool, a journey reflected in its regulatory approvals across multiple major jurisdictions. Its status and indications vary slightly by region, reflecting different regulatory timelines and public health needs.

7.1 Regulatory Approvals and Indications in the United States (FDA) and Europe (EMA)

• United States (FDA): The FDA approved JYNNEOS on September 24, 2019, for the prevention of smallpox and mpox disease in adults 18 years of age and older determined to be at high risk for infection.[33] This approval marked a significant milestone, providing a safer alternative to ACAM2000 for the U.S. Strategic National Stockpile.[33] During the 2022 mpox outbreak, the FDA acted swiftly to expand access, issuing an EUA on August 9, 2022. This EUA authorized the dose-sparing intradermal administration for adults and extended the vaccine's use via subcutaneous injection to individuals younger than 18 years.[2]
• Europe (EMA): The EMA initially granted marketing authorization for IMVANEX for smallpox prevention in 2013.[30] In July 2022, in response to the growing outbreak, the indication was formally extended to include the prevention of mpox disease.[30] Building on new clinical data, the EMA further extended the approval in September 2024 to include adolescents aged 12 to 17.[20] Separately, the EMA has also approved a recombinant MVA-based vaccine, Mvabea, developed by Janssen. Authorized in July 2020, Mvabea is indicated for the prevention of Ebola virus disease as part of a prime-boost regimen.[20]

Table 7.1: Global Regulatory Status of MVA-BN Based Vaccines
Brand Name
JYNNEOS
IMVAMUNE
IMVANEX
Mvabea (MVA-BN-Filo)

7.2 Regulatory Status and Use in Other Key Jurisdictions (Canada, Australia)

• Canada: Health Canada approved the vaccine under the brand name IMVAMUNE in 2013 for smallpox. The indication was expanded in 2020 to include mpox and related orthopoxvirus infections, placing Canada ahead of the U.S. and Europe in formally recognizing its utility for mpox.[2]
• Australia: The regulatory situation for JYNNEOS in Australia is distinct. The vaccine does not have full registration and is not listed on the Australian Register of Therapeutic Goods (ARTG).[54] Instead, it has been made available for the mpox response under a national emergency exemption mechanism provided by Section 18A of the Therapeutic Goods Act 1989.[56] This allows for its supply and use according to specific government-issued protocols. The Therapeutic Goods Administration (TGA) actively monitors the vaccine's safety through post-market surveillance programs like AusVaxSafety, which collected data from over 15,000 recipients during the outbreak and identified no new safety concerns.[58]

7.3 Role in National Stockpiles and Global Health Preparedness

MVA-BN's development was intrinsically linked to biodefense and public health preparedness. It was developed in collaboration with the U.S. government specifically to fill a critical gap in the Strategic National Stockpile (SNS): the need for a smallpox vaccine safe enough for the entire population, including the millions of immunocompromised individuals who could not receive ACAM2000.[20]

The 2022-2023 mpox outbreak transformed MVA-BN from a stockpiled countermeasure into a frontline global health asset. Bavarian Nordic rapidly scaled up production and supplied the vaccine to more than 70 countries to help control the outbreak.[20] This global deployment has also involved partnerships with supranational organizations like UNICEF to ensure access for African countries where mpox is endemic, highlighting its new role in addressing both emergency outbreaks and ongoing infectious disease threats.[20]

8.0 Conclusion and Future Directions

Modified Vaccinia Ankara stands as a testament to the power of strategic viral attenuation and platform-based vaccine design. Over half a century, it has evolved from a carefully crafted, safer alternative for smallpox vaccination into a critical tool for global public health emergencies and a promising vector for the next generation of vaccines and immunotherapies.

8.1 Synthesizing the Role of MVA in Modern Medicine

The journey of MVA encapsulates a paradigm shift in vaccinology. Its development demonstrated that a live virus could be rendered non-replicating in its target host, thereby achieving an unparalleled safety profile without completely abrogating its ability to induce a potent and comprehensive immune response. This "abortive infection" mechanism is the cornerstone of its success. The 2022 global mpox outbreak served as its definitive validation, where MVA-BN (JYNNEOS) proved to be a safe and effective tool for protecting at-risk populations, including those with compromised immune systems who were left vulnerable by older vaccines. Its deployment showcased the importance of maintaining robust biodefense stockpiles and the ability to pivot such assets to address emerging infectious disease threats. Today, MVA is not just a single product but a foundational technology, with its influence extending into the complex fields of HIV, Ebola, and cancer immunotherapy.

8.2 Future Research, Manufacturing Advancements, and Potential Applications

The future of the MVA platform is dynamic and expanding. Key areas of ongoing and future development include:

• Expansion to Pediatric Populations: With approval now secured for adolescents in Europe, ongoing clinical trials are assessing the safety and immunogenicity of MVA-BN in younger children (2-12 years), which could further broaden its indication and utility in family or household exposure scenarios.[20]
• Optimizing Vaccination Strategies: Research continues to refine how MVA-BN is best used, including studies to assess its efficacy as a post-exposure prophylactic to reduce secondary transmission within households and communities.[20]
• Manufacturing Advancements: A critical step toward ensuring broad and equitable global access is the modernization of MVA manufacturing. The transition from reliance on primary chicken embryo fibroblasts to scalable, continuous avian cell lines (such as the AGE.1 platform) promises to significantly increase production capacity, reduce costs, and enhance the ability to respond rapidly to future pandemics or large-scale outbreaks.[15]
• The Vector Pipeline: The most significant long-term potential of MVA lies in its role as a vector. The success of the Mvabea Ebola vaccine provides a powerful proof-of-concept. The extensive pipeline of MVA-vectored candidates for HIV, malaria, tuberculosis, and various cancers represents a major frontier in vaccine research.

In conclusion, Modified Vaccinia Ankara has firmly established its place as a vital component of the global public health armamentarium. Its unique combination of safety and immunogenicity makes it an indispensable tool for controlling orthopoxvirus outbreaks and a highly promising platform for tackling some of the most formidable infectious diseases and cancers of our time.

Works cited

1. Clinical development of Modified Vaccinia virus Ankara vaccines - Immunology, accessed October 22, 2025, https://www.immunology.ox.ac.uk/publications/426133
2. Modified vaccinia Ankara - Wikipedia, accessed October 22, 2025, https://en.wikipedia.org/wiki/Modified_vaccinia_Ankara
3. Monkeypox Vaccine Safety - CDC, accessed October 22, 2025, https://www.cdc.gov/vaccine-safety/vaccines/mpox.html
4. Clinical Review Memo, September 19, 2019 - JYNNEOS - FDA, accessed October 22, 2025, https://www.fda.gov/media/131870/download
5. vaccinia ankara mva: Topics by Science.gov, accessed October 22, 2025, https://www.science.gov/topicpages/v/vaccinia+ankara+mva
6. Comparison of Biological, Pharmacological Characteristics ..., accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9698380/
7. Monkeypox (Mpox) vaccines and their side effects: the other side of the coin - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10389550/
8. ACAM2000 (Smallpox Vaccine) Questions and Answers - FDA, accessed October 22, 2025, https://www.fda.gov/vaccines-blood-biologics/vaccines/acam2000-smallpox-vaccine-questions-and-answers
9. Safety and Efficacy of Repurposed Smallpox Vaccines Against Mpox ..., accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC12187628/
10. Development of Modified Vaccinia Virus Ankara-Based Vaccines ..., accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9503770/
11. Modified Vaccinia Virus Ankara: History, Value in Basic Research ..., accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7112317/
12. Modified Vaccinia Virus Ankara: History, Value in Basic Research, and Current Perspectives for Vaccine Development | Request PDF - ResearchGate, accessed October 22, 2025, https://www.researchgate.net/publication/305800221_Modified_Vaccinia_Virus_Ankara_History_Value_in_Basic_Research_and_Current_Perspectives_for_Vaccine_Development
13. Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications - MDPI, accessed October 22, 2025, https://www.mdpi.com/2076-393X/10/9/1516
14. Modified Vaccinia Ankara Virus Vaccination Provides Long-Term Protection against Nasal Rabbitpox Virus Challenge - ASM Journals, accessed October 22, 2025, https://journals.asm.org/doi/10.1128/cvi.00216-16
15. MVA Technology Overview - GeoVax, Inc., accessed October 22, 2025, https://www.geovax.com/technology/mva-technology-overview
16. A vital gene for modified vaccinia virus Ankara replication in human cells - PNAS, accessed October 22, 2025, https://www.pnas.org/doi/10.1073/pnas.2001335117
17. Safety and Efficacy of Repurposed Smallpox Vaccines Against Mpox: A Critical Review of ACAM2000, JYNNEOS, and LC16 - PubMed, accessed October 22, 2025, https://pubmed.ncbi.nlm.nih.gov/40553320/
18. Modified vaccinia ankara: Uses, Interactions, Mechanism of Action ..., accessed October 22, 2025, https://go.drugbank.com/drugs/DB15483
19. Viral Vector –based Therapeutic Cancer Vaccines - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3207353/
20. Bavarian Nordic Receives EMA Approval of Mpox Vaccine for Adolescents, accessed October 22, 2025, https://www.bavarian-nordic.com/investor/news/news.aspx?news=7000
21. Package Insert - JYNNEOS (Refrigerator) - FDA, accessed October 22, 2025, https://www.fda.gov/media/131078/download
22. JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Non-replicating), accessed October 22, 2025, https://jynneos.com/
23. Safety of mpox vaccines - World Health Organization (WHO), accessed October 22, 2025, https://www.who.int/groups/global-advisory-committee-on-vaccine-safety/topics/mpox
24. Smallpox Vaccine Safety - CDC, accessed October 22, 2025, https://www.cdc.gov/vaccine-safety/vaccines/smallpox.html
25. Mpox (monkeypox), Vaccines - Sanford Guide, accessed October 22, 2025, https://web.sanfordguide.com/en/prevention/vaccines/us-vaccine-guidelines/adult-special-populations/mpox_monkeypox-vaccines
26. Bavarian Nordic Submits Data to EMA to Extend Mpox/Smallpox Vaccine Approval to Adolescents, accessed October 22, 2025, https://www.bavarian-nordic.com/investor/news/news.aspx?news=6969
27. Study Details | NCT05740982 | A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox | ClinicalTrials.gov, accessed October 22, 2025, https://www.clinicaltrials.gov/study/NCT05740982
28. 2 doses - IMVANEX, INN-MVA-BN Smallpox and monkeypox vaccine - modified Vaccinia Virus Ankara, accessed October 22, 2025, https://ec.europa.eu/health/documents/community-register/2022/20220722156674/anx_156674_en.pdf
29. Safety Monitoring of JYNNEOS Vaccine During the 2022 Mpox Outbreak — United States, May 22–October 21, 2022 | MMWR - CDC, accessed October 22, 2025, https://www.cdc.gov/mmwr/volumes/71/wr/mm7149a4.htm
30. JYNNEOS (MVA-BN) Mpox Smallpox Vaccine — Vax-Before-Travel, accessed October 22, 2025, https://www.vax-before-travel.com/vaccines/jynneos-mva-bn-mpox-smallpox-vaccine
31. MVA-BN vaccine in response to mpox - Information Leaflet - HSE, accessed October 22, 2025, https://www.hse.ie/eng/health/immunisation/hcpinfo/hse-mpox-mva-bn-vaccine-response-information-leaflet-december-2024.pdf
32. Studies show efficacy, safety of Jynneos vaccine against mpox - CIDRAP, accessed October 22, 2025, https://www.cidrap.umn.edu/covid-19/studies-show-efficacy-safety-jynneos-vaccine-against-mpox
33. Key Facts About Vaccines to Prevent Mpox Disease - FDA, accessed October 22, 2025, https://www.fda.gov/vaccines-blood-biologics/vaccines/key-facts-about-vaccines-prevent-mpox-disease
34. FDA approved vaccines for monkeypox: Current eminence - PMC - PubMed Central, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9628798/
35. Short-term Adverse Events Following Immunization With Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) Vaccine for Mpox - PMC, accessed October 22, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10282881/
36. Mpox (previously known as monkeypox) | The Australian ..., accessed October 22, 2025, https://immunisationhandbook.health.gov.au/contents/vaccine-preventable-diseases/mpox-previously-known-as-monkeypox
37. www.bavarian\-nordic.com, accessed October 22, 2025, https://www.bavarian-nordic.com/investor/news/news.aspx?news=7000#:~:text=While%20this%20represents%20the%20first,%E2%89%A51%20year%20of%20age.
38. The Mpox Vaccine, MVA-BN, Receives Approval for Use in Adolescents 12 - 17 years of age, accessed October 22, 2025, https://gwvru.smhs.gwu.edu/news/mpox-vaccine-mva-bn-receives-approval-use-adolescents-12-17-years-age
39. Smallpox and Mpox Vaccine Patient Drug Record | NIH - Clinical Info HIV.gov, accessed October 22, 2025, https://clinicalinfo.hiv.gov/en/drugs/smallpox-and-mpox-vaccine/patient
40. Multivalent and Multipathogen Viral Vector Vaccines - ASM Journals, accessed October 22, 2025, https://journals.asm.org/doi/10.1128/cvi.00298-16
41. Intravenous Injection of MVA Virus Targets CD8 + Lymphocytes to Tumors to Control Tumor Growth upon Combinatorial Treatment with a TLR9 Agonist - AACR Journals, accessed October 22, 2025, https://aacrjournals.org/cancerimmunolres/article/2/12/1163/467244/Intravenous-Injection-of-MVA-Virus-Targets-CD8
42. Modified vaccinia ankara Completed Phase 1 Trials for Human Immunodeficiency Virus (HIV) Infections Prevention - DrugBank, accessed October 22, 2025, https://go.drugbank.com/drugs/DB15483/clinical_trials?conditions=DBCOND0035016&phase=1&purpose=prevention&status=completed
43. Modified vaccinia ankara Completed Phase 2 Trials for Human Immunodeficiency Virus (HIV) Infections Treatment - DrugBank, accessed October 22, 2025, https://go.drugbank.com/drugs/DB15483/clinical_trials?conditions=DBCOND0035016&phase=2&purpose=treatment&status=completed
44. Mvabea | European Medicines Agency (EMA), accessed October 22, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/mvabea
45. Full article: Harnessing live vectors for cancer vaccines: Advancing therapeutic immunotherapy - Taylor & Francis Online, accessed October 22, 2025, https://www.tandfonline.com/doi/full/10.1080/21645515.2025.2469416
46. Modified vaccinia ankara Completed Phase 1 Trials for Lung Cancer / Ovarian Cancer / Breast Cancer / Prostate Cancer / Tumors (Others) Treatment - DrugBank, accessed October 22, 2025, https://go.drugbank.com/drugs/DB15483/clinical_trials?conditions=DBCOND0028036%2CDBCOND0028388%2CDBCOND0028213%2CDBCOND0062462%2CDBCOND0071005&phase=1&purpose=treatment&status=completed
47. Clinical trial investigates IV administration of vaccine for advanced solid tumors, accessed October 22, 2025, https://ccr.cancer.gov/news/article/clinical-trial-investigates-iv-administration-of-vaccine-for-advanced-solid-tumors
48. Modified vaccinia ankara Completed Phase 2 Trials for Hepatocellular Carcinoma Treatment | DrugBank Online, accessed October 22, 2025, https://go.drugbank.com/drugs/DB15483/clinical_trials?conditions=DBCOND0030090&phase=2&purpose=treatment&status=completed
49. Melanoma Completed Phase 1 / 2 Trials for Modified vaccinia ankara (DB15483), accessed October 22, 2025, https://go.drugbank.com/indications/DBCOND0020306/clinical_trials/DB15483?phase=1%2C2&status=completed
50. www.cdc.gov, accessed October 22, 2025, https://www.cdc.gov/vaccine-safety/vaccines/mpox.html#:~:text=Live%2C%20replication%2Ddeficient%20MVA%20vaccine,for%20smallpox%20or%20monkeypox%20infection.
51. JYNNEOS and TPOXX for Monkeypox VHA PBM Frequently Asked Questions (FAQ): - VA.gov, accessed October 22, 2025, https://www.va.gov/formularyadvisor/DOC_PDF/FAQ_VA_Monkeypox_vaccine_and_therapeutic_FAQ_V4_Oct_1_2022_Update.pdf
52. JYNNEOS | FDA, accessed October 22, 2025, https://www.fda.gov/vaccines-blood-biologics/jynneos
53. Australian Register of Therapeutic Goods (ARTG) | Therapeutic ..., accessed October 22, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
54. Mpox vaccines – frequently asked questions (FAQs) | NCIRS, accessed October 22, 2025, https://ncirs.org.au/ncirs-fact-sheets-faqs-and-other-resources/mpox-vaccines-frequently-asked-questions-faqs
55. JYNNEOS vaccine consent, supply and administration in NSW, accessed October 22, 2025, https://www.health.nsw.gov.au/Infectious/factsheets/Pages/mpxv-protocol.aspx
56. State-wide Protocol for the Supply and Administration of JYNNEOS Vaccine - NSW Health, accessed October 22, 2025, https://www.health.nsw.gov.au/Infectious/Documents/mpxv-protocol.pdf
57. Mpox (monkeypox) vaccine | AusVaxSafety, accessed October 22, 2025, https://ausvaxsafety.org.au/vaccine-safety-data/mpox-monkeypox-vaccine
58. Subcutaneous JYNNEOS mpox (monkeypox) vaccine - AusVaxSafety, accessed October 22, 2025, https://ausvaxsafety.org.au/mpox-monkeypox-vaccine/subcutaneous-jynneos-mpox-monkeypox-vaccine
59. Vaccines overview | Therapeutic Goods Administration (TGA), accessed October 22, 2025, https://www.tga.gov.au/products/medicines/vaccines-overview